Navigation Links
Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results
Date:11/6/2008

Nexavar Net Sales increase 73% over Third Quarter 2007

EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and nine months ended September 30, 2008. Onyx reported net income of $12.2 million, or $0.21 per diluted share, for the third quarter of 2008 compared to net income of $0.6 million, or $0.01 per diluted share, in the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net income for the third quarter of 2008 was $16.6 million, or $0.29 per diluted share, compared to a non-GAAP net income of $4.2 million, or $0.08 per diluted share, in the same period in 2007. A description of the non-GAAP calculations are provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.

Global Nexavar net sales as reported by Bayer HealthCare Pharmaceuticals, Inc., or Bayer, were $180.9 million for the quarter ended September 30, 2008, a 73% increase over the $104.6 million reported in the same period in 2007. Onyx with its collaborator, Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the U.S., European Union, and other territories internationally.

"As demonstrated by Nexavar's continued sales growth, we are further building our leadership in the liver cancer market with ongoing product launches in multiple countries, including Italy and China," said Tony Coles, M.D., president and chief executive officer of Onyx. "The significant growing commercial contribution from Nexavar allows us to continue to invest in additional possible indications for Nexavar, as well
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents
2. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
3. Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
4. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
5. Jazz Pharmaceuticals to Present at Investor Conferences
6. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
8. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
9. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
10. Genesis Pharmaceuticals Files Counter Claims
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... new weight management program that is unique to the Lake Orion area. This ... and Macomb County. , WEmovestrong’s weight management program will incorporate group fitness ...
(Date:8/31/2015)... Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... start from and those who are interested in learning more about the procedure beyond ... Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be on ...
(Date:8/31/2015)... Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... journal article from the Plastic and Reconstructive Surgery Global Open Journal that discusses the ... general. The article discussed how, in the future, customized implants, prosthetics, and other 3-D ...
(Date:8/31/2015)... ... 31, 2015 , ... Since 1946, the doctors and staff at Clifton Dental ... a patient arrives at the office, the staff will make them feel welcome and ... patient to create a complete dental treatment plan that is unique to each smile! ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Stewart Shofner ... be prevented during Amblyopia Awareness Month. Only a comprehensive eye examination can diagnose amblyopia. ... cause of visual impairment among children, affecting approximately 2 to 3 out of every ...
Breaking Medicine News(10 mins):Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3
... Market Intelligence and Strategic Analysis responds to customer needs by merging ... giving the group 10 offices across three continents and greater access ... ... Helsinki (PRWEB) October 14, 2008 -- Global Intelligence Alliance (GIA, ...
... warehouse supply market with broad based labeling, packing slip and ... , ... Fort Scott, KS (PRWEB) October ... include industry specific solutions for warehouse and distribution centers that ...
... (October 14, 2008) Patients have on average ... the nation,s top-rated hospitals compared with the lowest-rated ... the eleventh annual HealthGrades Hospital Quality in America ... healthcare ratings organization. , While overall death ...
... announced,today that St. Peter,s Hospital in Albany, NY, has ... its discharge instruction,compliance for heart failure patients from 85.4 ... St. Peter,s Hospital, part of St. Peter,s Health ... in the nation named for eight years as,a Thomson ...
... come with other NSAID pain relievers, experts say , , MONDAY, ... pulled from the market in 2004 -- over concerns that it ... assumed that stopping the drug would end the risk. , ... to twofold, and the risk persisted for approximately a year," said ...
... CITY, Utah, Oct. 13 Nutraceutical,International Corporation (Nasdaq: ... and Cory McQueen, Vice President and Chief Financial ... Company on Wednesday,October 15, 2008 at the Canaccord ... is scheduled for 2:30 PM Eastern,Time that day ...
Cached Medicine News:Health News:Global Intelligence Alliance Strengthens Group Organization and Adds Local Presence, Merges With Asian, German and Dutch Partner Companies 2Health News:My1Stop.com Offers Industry Specific Printing, Packing Slip and Labeling Solutions for Warehouse, Fulfillment and Distribution Centers 2Health News:My1Stop.com Offers Industry Specific Printing, Packing Slip and Labeling Solutions for Warehouse, Fulfillment and Distribution Centers 3Health News:Death rate 70 percent lower at top-rated hospitals: HealthGrades annual hospital quality study 2Health News:Death rate 70 percent lower at top-rated hospitals: HealthGrades annual hospital quality study 3Health News:St. Peter's Hospital of Albany Improves Core Measures Processes 2Health News:St. Peter's Hospital of Albany Improves Core Measures Processes 3Health News:Vioxx's Heart Risk Lingered Long After Use Ended 2Health News:Vioxx's Heart Risk Lingered Long After Use Ended 3Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 2Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 3
(Date:8/31/2015)...  Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a ... of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, ... four investor conferences in September. , ... Company, LLC Emerging Growth Conference in ... , President & Chief Executive Officer, will present a ...
(Date:8/31/2015)... Israel , August 31, 2015 ... (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the ... commercializes biomedical innovations in ophthalmology and cancer diagnostics, ... Technologies (TASE: MCTC), has identified several new genetic ... the jawbone in patients treated with bisphosphonate drugs ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... , NEW YORK ... (Sony) announced today that it has acquired iCyt Mission Technology, Inc. ... cell and disease research, through its U.S. subsidiary, Sony Corporation of ... technologies to enter the flow cytometry business in the life science ...
... , Feb. 9 STD Med, Inc., a manufacturer ... is pleased to announce the acquisition of a new 32,000 sq. ... addition to the current footprint of 120,000 sq. ft. "We are ... financial times," said Steven Tallarida , President STD Med, "we ...
Cached Medicine Technology:Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: